Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease

Movement Disorders

Volumn 26, Issue 4, 2011, Pages 664-670

  Merola, Aristide ^a   Zibetti, Maurizio ^a   Angrisano, Serena ^a   Rizzi, Laura ^a   Lanotte, Michele ^a   Lopiano, Leonardo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Levodopa carbidopa enteral infusion; Parkinson's disease; Subthalamic nucleus deep brain stimulation

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; APRAXIA; ARTICLE; BECK DEPRESSION INVENTORY; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; EXECUTIVE FUNCTION; FOLLOW UP; GASTROSTOMY; HUMAN; INTESTINE OBSTRUCTION; LEARNING; MEMORY; ONSET AGE; OPTIMAL DRUG DOSE; PARKINSON DISEASE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; SUBTHALAMIC NUCLEUS; SUBTHALAMIC NUCLEUS BRAIN DEPTH STIMULATION; VERBAL BEHAVIOR; WEIGHT REDUCTION;

AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DEEP BRAIN STIMULATION; DISABILITY EVALUATION; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; SUBTHALAMIC NUCLEUS; TREATMENT OUTCOME;

EID: 79955019815     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23524     Document Type: Article

References (33)

1. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006; 63: 205-209.
2. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-458.
3. Sweet RD, McDowell FH. The "on-off" response to chronic L-DOPA treatment of Parkinsonism. Adv Neurol 1974; 5: 331-338.
4. Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 728-741.
5. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003; 349: 1925-1934.
6. Fahn S, Elton R, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors.Recent Developments in Parkinson's Disease, Vol. 2. Florham Park, NJ: Macmillan Health Care Information; 1987. p 153-163.
7. Schupbach WM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1640-1644.
8. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005; 128: 2240-2249.
9. Wider C, Pollo C, Bloch J, Burkhard PR, Vingerhoets FJ. Long-term outcome of 50 consecutive Parkinson's disease patients treated with subthalamic deep brain stimulation. Parkinsonism Relat Disord 2008; 14: 114-119.
10. Gervais-Bernard H, Xie-Brustolin J, Mertens P, et al. Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up. J Neurol 2009; 256: 225-233.
11. Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008; 23: 1130-1136.
12. De Gaspari D, Siri C, Landi A, et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006; 77: 450-453.
13. Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand 2009; 119: 345-348.
14. Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986; 20: 262-265.
15. Sage JI, Trooskin S, Sonsalla PK, Heikkila R, Duvoisin RC. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988; 24: 87-89.
16. Syed N, Murphy J, Zimmerman T, Jr., Mark MH, Sage JI. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998; 13: 336-338.
17. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-223.
18. Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. Expert Rev Neurother 2009; 9: 859-867.
19. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999; 14: 572-584.
20. Lanotte MM, Rizzone M, Bergamasco B, Faccani G, Melcarne A, Lopiano L. Deep brain stimulation of the subthalamic nucleus: anatomical, neurophysiological, and outcome correlations with the effects of stimulation. J Neurol Neurosurg Psychiatry 2002; 72: 53-58.
21. Antonini A, Mancini F, Canesi M, et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 2008; 5: 244-246.
22. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009; 24: 993-1000.
23. Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008; 31: 151-166.
24. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007; 22: 1145-1149.
25. Castelli L, Rizzi L, Zibetti M, Angrisano S, Lanotte M, Lopiano L. Neuropsychological changes 1-year after subthalamic DBS in PD patients: a prospective controlled study. Parkinsonism Relat Disord 2010; 16: 115-118.
26. Morrison CE, Borod JC, Perrine K, et al. Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson's disease. Arch Clin Neuropsychol 2004; 19: 165-181.
27. York MK, Dulay M, Macias A, et al. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 2008; 79: 789-795.
28. Wolters E. Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2007; 13 Suppl: S18-S23.
29. Isacson D, Bingefors K, Kristiansen IS, Nyholm D. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand 2008; 118: 379-386.
30. Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008; 31: 63-73.
31. Hariz MI. Complications of deep brain stimulation surgery. Mov Disord 2002; 17 ( Suppl 3): S162-S166.
32. Deuschl G, Herzog J, Kleiner-Fisman G, et al. Deep brain stimulation: postoperative issues. Mov Disord 2006; 21 ( Suppl 14): S219-S237.
33. Lang AE, Houeto JL, Krack P, et al. Deep brain stimulation: preoperative issues. Mov Disord 2006; 21 ( Suppl 14): S171-S196.